3-GOLD-22-Infographic-Banner-Template-1584-x-396.jpg
  • LinkedIn
  • EMG

Access to medicine in Latin America

Access to medicine around the world is still a huge and disparate issue, most notably in developing countries. Here, GOLD tracks the access landscape in Latin America by examining medicine spending over the last five years and standout examples of ongoing initiatives founded by pharmaceutical companies to improve access in the region

GOLD tracks the access landscape in Latin America by examining medicine spending over the last five years and standout examples of ongoing initiatives founded by pharmaceutical companies to improve access in the region.

infographic_22.jpg

Before the pandemic, projections for R&D productivity were at a decade-long decline, but internal rate of return started increasing in 2020. GOLD examines how the R&D pipeline is evolving, looking at the companies leading the way and potential triggers for the recent spike.

gold_infographic_21.jpg

The pharmaceutical industry’s supply chain is a challenging system to maintain and protect, especially in the wake of COVID-19 disruptions. With all kinds of unpredictable events having the potential to impact the industry’s complex distribution network, resilience is key.

infographic_gold_20.jpg

GOLD's infographic archive

Click the navigation arrows to scroll through each of GOLD's past infographics. Click on an infographic to expand and download.

press to zoom

press to zoom

press to zoom

press to zoom
1/24

YOU MIGHT ALSO LIKE.. 

R&D

Time to
tackle AMR
GOLD-22-time-to-tackle-AMR-superbugs-antibiotics.jpg

How is the pharmaceutical industry responding to the public health crisis of antimicrobial resistance?

Marketing

Achieving first-time launch success 
GOLD-22-first-time-launch-success.jpg

Examining the first-time launch landscape, GOLD explores how emerging pharma companies can succeed when bringing their first products to market.  

International

Pharma in
Brazil
GOLD-22-pharma-in-Brazil.jpg

GOLD journeys to the shores of Brazil to examine its pharmaceutical landscape and considers its response to COVID-19, access challenges and more.

Never miss an update, subscribe!